Identification/NN
of/IN
Genetic/JJ
Variations/NNS
in/IN
CBL/NN
,/,
SORBS1/NN
,/,
CRK/NN
,/,
and/CC
RHOQ/NN
,/,
Key/NNP
Modulators/NNS
in/IN
the/DT
CAP/TC10/NN
Pathway/NN
of/IN
Insulin/NN
Signal/NN
Transduction/NN
,/,
and/CC
Their/PRP$
Association/NN
with/IN
Type/NN
2/CD
Diabetes/NNS
Mellitus/NN
in/IN
the/DT
Korean/JJ
Population/NN
./.
====================
Recent/JJ
evidence/NN
has/VBZ
strongly/RB
suggested/VBD
that/IN
the/DT
CAP/TC10/NN
pathway/NN
is/VBZ
involved/VBN
in/IN
the/DT
trafficking/VBG
,/,
docking/NN
,/,
and/CC
fusion/NN
of/IN
vesicles/NNS
containing/VBG
the/DT
insulin-responsive/JJ
glucose/NN
transporter/NN
Glut4/NN
to/TO
the/DT
plasma/NN
membrane/NN
./.
====================
However/RB
,/,
little/JJ
is/VBZ
known/VBN
about/IN
how/WRB
the/DT
genes/NNS
employed/VBN
in/IN
the/DT
CAP/TC10/NN
pathway/NN
are/VBP
associated/VBN
with/IN
the/DT
development/NN
of/IN
type/NN
2/CD
diabetes/NNS
mellitus/NN
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
sequenced/VBD
4/CD
genes/NNS
of/IN
the/DT
CAP/TC10/NN
pathway/NN
[/(
SORBS1/NN
,/,
CBL/NN
,/,
CRK/NN
,/,
and/CC
RHOQ/NN
]/)
in/IN
24/CD
individuals/NNS
to/TO
identify/VB
genetic/JJ
variations/NNS
in/IN
these/DT
loci/NNS
./.
====================
A/DT
total/JJ
of/IN
48/CD
sequence/NN
variants/NNS
were/VBD
identified/VBN
,/,
including/VBG
23/CD
novel/JJ
variations/NNS
./.
====================
To/TO
investigate/VB
the/DT
possible/JJ
association/NN
with/IN
type/NN
2/CD
diabetes/NNS
mellitus/NN
,/,
3/CD
single/JJ
nucleotide/NN
polymorphisms/NNS
from/IN
SORBS1/NN
,/,
3/CD
from/IN
CBL/NN
,/,
and/CC
4/CD
from/IN
RHOQ/NN
were/VBD
genotyped/VBN
in/IN
1122/CD
Korean/JJ
type/NN
2/CD
diabetic/JJ
patients/NNS
and/CC
1138/CD
nondiabetic/JJ
controls/NNS
./.
====================
Using/VBG
logistic/JJ
regression/NN
analysis/NN
,/,
1/CD
significant/JJ
association/NN
between/IN
SNP/NN
rs1376405/NN
in/IN
RHOQ/NN
and/CC
type/NN
2/CD
diabetes/NNS
mellitus/NN
[/(
OR/NN
=/JJ
8.714/CD
(/(
C./FW
I/NN
./.
====================
1.714-44.29/CD
)/)
,/,
p/NN
=/JJ
0.009/CD
]/)
was/VBD
found/VBN
in/IN
the/DT
recessive/JJ
model/NN
./.
====================
Our/PRP$
data/NNS
demonstrate/VBP
a/DT
positive/JJ
association/NN
of/IN
the/DT
RHOQ/NN
gene/NN
in/IN
the/DT
CAP/TC10/NN
pathway/NN
with/IN
T2DM/NN
in/IN
the/DT
Korean/JJ
population/NN
./.
====================
During/IN
recent/JJ
years/NNS
,/,
major/JJ
advances/NNS
have/VBP
been/VBN
made/VBN
in/IN
our/PRP$
understanding/NN
of/IN
insulin/NN
actions/NNS
./.
====================
In/IN
the/DT
cell/NN
,/,
the/DT
recognition/NN
of/IN
insulin/NN
by/IN
insulin/NN
receptor/NN
instigates/NNS
phosphorylation/NN
of/IN
several/JJ
intracellular/JJ
substrates/NNS
,/,
such/JJ
as/IN
the/DT
insulin/NN
receptor/NN
substrates/NNS
(/(
IRS14/NN
)/)
(/(
White/IN
and/CC
Yenush/RB
,/,
1998/CD
)/)
,/,
calcineurin/NN
Blike/IN
protein/NN
1/CD
(/(
Cbl1/NN
)/)
(/(
Ribon/NNP
and/CC
Saltiel/JJ
,/,
1997/CD
)/)
,/,
Src/NN
homology/NN
2/CD
domaincontaining/JJ
transforming/VBG
protein/NN
(/(
Shc/NN
)/)
(/(
Sasaoka/NNP
et/FW
al./FW
,/,
1994/CD
)/)
,/,
SH2B/NN
adaptor/NN
protein/NN
2/CD
(/(
SH2B2/NN
)/)
(/(
Liu/NNP
et/FW
al./FW
,/,
2002/CD
)/)
,/,
and/CC
p60DOK/NN
(/(
Noguchi/NNP
et/FW
al./FW
,/,
1999/CD
)/)
./.
====================
Defects/NNS
in/IN
genes/NNS
involved/VBN
in/IN
the/DT
insulin/NN
signaling/NN
pathway/NN
are/VBP
linked/VBN
to/TO
the/DT
pathogenesis/NN
of/IN
type/NN
II/CD
diabetes/NNS
mellitus/NN
(/(
T2DM/NN
)/)
(/(
Zierath/NN
and/CC
WallbergHenriksson/NN
,/,
2002/CD
)/)
./.
====================
In/IN
the/DT
CAP/TC10/NN
pathway/NN
,/,
the/DT
insulin/NN
receptor/NN
recruits/VBZ
and/CC
phosphorylates/VBZ
Cbl/NN
proteins/NNS
through/IN
an/DT
intermediary/JJ
adaptor/NN
protein/NN
called/VBN
SH2B2/NN
(/(
Liu/NNP
,/,
et/FW
al./FW
,/,
2002/CD
)/)
./.
====================
Binding/NN
of/IN
the/DT
SH2/NN
domain/NN
of/IN
SH2B2/NN
to/TO
the/DT
phosphorylated/VBN
insulin/NN
receptor/NN
facilitates/NNS
phosphorylation/NN
of/IN
SH2B2/NN
,/,
which/WDT
then/RB
serves/VBZ
as/IN
a/DT
docking/NN
site/NN
for/IN
Cbl/NN
(/(
Hu/NNP
and/CC
Hubbard/JJ
,/,
2005/CD
)/)
./.
====================
Another/DT
adaptor/NN
protein/NN
,/,
termed/VBN
sorbin/NN
,/,
and/CC
SH2/NN
domaincontaining/JJ
1/CD
(/(
SORBS1/NN
)/)
,/,
which/WDT
is/VBZ
a/DT
human/JJ
homolog/NN
of/IN
Cblassociated/JJ
protein/NN
(/(
CAP/NN
)/)
,/,
are/VBP
involved/VBN
in/IN
the/DT
targeting/VBG
of/IN
Cbl/NN
to/TO
lipid/NN
raft/NN
microdomains/NNS
(/(
Ribon/NN
et/FW
al./FW
,/,
1998/CD
)/)
./.
====================
Upon/IN
phosphorylation/NN
of/IN
Cbl/NN
,/,
the/DT
Cbl/CAP/NN
complex/NN
provides/VBZ
docking/NN
sites/NNS
for/IN
the/DT
recruitment/NN
of/IN
the/DT
adaptor/NN
protein/NN
CRKII/NN
and/CC
the/DT
guanyl/NN
nucleotide/NN
exchange/NN
factor/NN
C3G/NN
(/(
Baumann/NN
et/FW
al./FW
,/,
2000/CD
;/:
Ribon/NN
et/FW
al./FW
,/,
1996/CD
)/)
./.
====================
Recruitment/JJ
of/IN
C3G/NN
results/NNS
in/IN
the/DT
activation/NN
of/IN
the/DT
small/JJ
GTPbinding/JJ
TC10/NN
(/(
protein/NN
product/NN
of/IN
the/DT
RHOQ/NN
gene/NN
)/)
./.
====================
Activation/NN
of/IN
TC10/NN
results/NNS
in/IN
cytoskeletal/JJ
rearrangements/NNS
that/IN
are/VBP
needed/VBN
to/TO
facilitate/VB
Glut4/NN
translocation/NN
upon/IN
insulin/NN
signaling/NN
as/IN
well/RB
as/IN
insulinstimulated/VBN
glucose/NN
uptake/NN
(/(
Chiang/NNP
et/FW
al./FW
,/,
2001/CD
)/)
./.
====================
A/DT
recent/JJ
study/NN
of/IN
streptozotocininduced/JJ
diabetic/JJ
animals/NNS
showed/VBD
that/IN
Cbl/NN
and/CC
SORBS1/NN
gene/NN
expression/NN
was/VBD
significantly/RB
reduced/VBD
and/CC
that/IN
the/DT
activation/NN
of/IN
TC10/NN
was/VBD
also/RB
abridged/VBD
(/(
Gupte/NNP
and/CC
Mora/NN
,/,
2006/CD
)/)
./.
====================
In/IN
spite/NN
of/IN
the/DT
pivotal/JJ
role/NN
of/IN
the/DT
CAP/TC10/NN
pathway/NN
in/IN
skeletal/JJ
muscle/NN
and/CC
adipose/NN
tissue/NN
,/,
the/DT
association/NN
of/IN
effector/NN
genes/NNS
with/IN
T2DM/NN
has/VBZ
not/RB
been/VBN
elucidated/VBN
well/RB
./.
====================
In/IN
the/DT
present/JJ
report/NN
,/,
we/PRP
investigated/VBD
the/DT
genetic/JJ
var/JJ
iations/NNS
of/IN
4/CD
genes/NNS
encoding/VBG
major/JJ
components/NNS
of/IN
the/DT
CAP/TC10/NN
pathway-SORBS1/NN
,/,
CBL/NN
,/,
CRK/NN
,/,
and/CC
RHOQ/NN
and/CC
analyzed/VBD
the/DT
association/NN
of/IN
their/PRP$
genetic/JJ
variations/NNS
with/IN
T2DM/NN
./.
====================
We/PRP
studied/VBD
1,122/CD
type/NN
2/CD
diabetic/JJ
cases/NNS
(/(
586/CD
men/NNS
and/CC
536/CD
women/NNS
;/:
age/NN
56.2±8.80/CD
years/NNS
(/(
mean±SD/NN
)/)
,/,
BMI/NNP
25.4±3.31/CD
kg/m2/NN
)/)
and/CC
1,138/NN
nondiabetic/JJ
controls/NNS
(/(
516/CD
men/NNS
and/CC
622/CD
women/NNS
;/:
age/NN
64.2±2.87/CD
years/NNS
,/,
BMI/NNP
23.7/CD
±3.7/CD
kg/m2/NN
)/)
./.
====================
Diabetic/JJ
patients/NNS
were/VBD
recruited/VBN
from/IN
a/DT
Korean/JJ
prospective/JJ
community/NN
cohort/NN
study/NN
(/(
Ansung/NN
Ansan/NN
)/)
according/VBG
to/TO
WHO/NN
criteria/NNS
./.
====================
Nondiabetic/JJ
controls/NNS
had/VBD
no/DT
history/JJ
of/IN
diabetes/NNS
and/CC
had/VBD
fasting/JJ
plasma/NN
glucose/NN
levels/NNS
less/RBR
than/IN
6.1/CD
mmol/L/NN
and/CC
hemoglobin/NN
A1c/NN
(/(
HbA1c/NN
)/)
levels/NNS
less/RBR
than/IN
5.8/CD
%/NN
./.
====================
The/DT
study/NN
was/VBD
approved/VBN
by/IN
the/DT
institutional/JJ
review/NN
board/JJ
of/IN
the/DT
Korean/JJ
National/JJ
Institute/JJ
of/IN
Health/NN
./.
====================
Written/RB
informed/VBN
consent/NN
was/VBD
obtained/VBN
from/IN
all/DT
subjects/NNS
./.
====================
The/DT
clinical/JJ
characteristics/NNS
of/IN
subjects/NNS
are/VBP
shown/VBN
in/IN
Table/JJ
1/CD
./.
====================
We/PRP
sequenced/VBD
all/DT
exons/NNS
,/,
including/VBG
exonintron/NN
boundaries/NNS
,/,
and/CC
the/DT
promoter/NN
region/NN
(/(
approximately/RB
1.5/CD
kb/NN
)/)
to/TO
discover/RB
single/JJ
nucleotide/NN
polymorphisms/NNS
(/(
SNPs/NNS
)/)
in/IN
24/CD
Korean/NN
DNA/NN
samples/NNS
using/VBG
the/DT
ABI/NN
PRISM/NN
3730/CD
DNA/NN
analyzer/NN
(/(
Applied/VBN
Biosystems/NNS
,/,
Foster/NN
City/NN
,/,
CA/NNP
,/,
USA/NNP
)/)
./.
====================
Twentyeight/CD
primer/NN
sets/NNS
for/IN
the/DT
amplification/NN
and/CC
sequencing/NN
analysis/NN
were/VBD
designed/VBN
based/VBN
on/IN
sequence/NN
information/NN
from/IN
GenBank/NN
./.
====================
Detailed/JJ
description/NN
about/RB
primers/NNS
is/VBZ
available/JJ
in/IN
Supplementary/JJ
Table/JJ
1/CD
./.
====================
Individual/JJ
sequence/NN
variants/NNS
were/VBD
verified/VBN
on/IN
chromatograms/NNS
./.
====================
The/DT
10/CD
SNPs/NNS
were/VBD
selected/VBN
for/IN
genotyping/VBG
based/VBN
on/IN
haplotype/NN
tagging/VBG
and/CC
minor/JJ
allele/NN
frequency/NN
(/(
＞0.5/CD
%/NN
)/)
./.
====================
SNPs/NNS
were/VBD
genotyped/VBN
using/VBG
amplifying/VBG
primers/NNS
and/CC
probes/NNS
designed/VBN
for/IN
TaqMan/NN
(/(
Livak/NN
,/,
1999/CD
)/)
./.
====================
The/DT
Primer/NN
Express/NN
(/(
Applied/VBN
Biosystems/NNS
)/)
program/NN
was/VBD
used/VBN
to/TO
design/VB
both/CC
the/DT
PCR/NN
primers/NNS
and/CC
the/DT
MGB/NN
TaqMan/NN
probes/NNS
./.
====================
Information/NN
regarding/VBG
primers/NNS
and/CC
probes/NNS
is/VBZ
available/JJ
in/IN
Supplementary/JJ
Table/JJ
2/CD
./.
====================
The/DT
detailed/JJ
experimental/JJ
procedures/NNS
can/MD
be/VB
found/VBN
in/IN
Park/NN
et/FW
al/JJ
./.
====================
(/(
2006/CD
)/)
./.
====================
To/TO
determine/VB
whether/IN
each/DT
individual/JJ
variant/JJ
was/VBD
in/IN
equilibrium/NN
at/IN
each/DT
locus/NN
in/IN
the/DT
population/NN
(/(
Hardy/NN
Weinberg/NN
equilibrium/NN
)/)
,/,
χ2/NN
tests/NNS
were/VBD
applied/VBN
./.
====================
We/PRP
examined/VBD
the/DT
linkage/NN
disequilibrium/NN
(/(
LD/NN
)/)
coefficient/JJ
,/,
γ2/NN
,/,
between/IN
all/DT
pairs/NNS
of/IN
biallelic/JJ
loci/NNS
(/(
Hedrick/JJ
and/CC
Kumar/JJ
,/,
2001/CD
)/)
./.
====================
Genotype/NN
frequencies/NNS
were/VBD
compared/VBN
between/IN
patients/NNS
and/CC
controls/VBZ
in/IN
3/CD
different/JJ
modes/NNS
(/(
codominant/JJ
,/,
dominant/JJ
,/,
and/CC
recessive/JJ
)/)
by/IN
using/VBG
logistic/JJ
regression/NN
while/IN
controlling/VBG
for/IN
age/NN
,/,
sex/NN
,/,
and/CC
BMI/NN
./.
====================
Genotypes/NNS
were/VBD
given/VBN
codes/VBZ
of/IN
0/CD
,/,
1/CD
,/,
and/CC
2/CD
;/:
0/CD
,/,
1/CD
,/,
and/CC
1/CD
;/:
and/CC
0/CD
,/,
0/CD
,/,
and/CC
1/CD
in/IN
the/DT
codominant/JJ
,/,
dominant/JJ
,/,
and/CC
recessive/JJ
models/NNS
,/,
respectively/RB
./.
====================
The/DT
SAS/NN
statistical/JJ
software/NN
package/NN
(/(
SAS/NN
Institute/JJ
Inc./NNP
Cary/NN
,/,
NC/NN
,/,
USA/NN
)/)
was/VBD
used/VBN
to/TO
perform/VB
general/JJ
statistical/JJ
analyses/NNS
./.
====================
Statistical/JJ
significance/NN
was/VBD
determined/VBN
by/IN
a/DT
two-tailed/JJ
value/NN
of/IN
p＜0.05/NN
for/IN
logistic/JJ
regression/NN
./.
====================
To/TO
discover/RB
genetic/JJ
variations/NNS
in/IN
the/DT
tested/VBN
genes/NNS
,/,
we/PRP
sequenced/VBD
all/DT
exons/NNS
and/CC
their/PRP$
boundaries/NNS
,/,
including/VBG
1.5/CD
kb/NN
upstream/RB
of/IN
the/DT
SORBS1/NN
,/,
CBL/NN
,/,
CRK/NN
,/,
and/CC
TC10/NN
genes/NNS
,/,
in/IN
the/DT
DNA/NN
samples/NNS
of/IN
24/CD
unrelated/JJ
Koreans/NNS
./.
====================
We/PRP
identified/VBD
48/CD
sequence/NN
variants/NNS
(/(
including/VBG
23/CD
novel/JJ
polymorphisms/NNS
)/)
:/:
15/CD
SNPs/NNS
in/IN
the/DT
promoter/NN
region/NN
(/(
1/LS
SNP/NN
in/IN
CRK/NN
,/,
8/CD
SNPs/NNS
in/IN
SORBS1/NN
,/,
and/CC
6/CD
SNPs/NNS
in/IN
RHOQ/NNP
)/)
,/,
1/LS
SNP/NN
in/IN
the/DT
5/CD
’/NNP
UTR/NN
of/IN
CBL/NN
,/,
2/CD
synonymous/JJ
SNPs/NNS
in/IN
coding/VBG
sequences/NNS
(/(
1/LS
SNP/NN
in/IN
CBL/NN
and/CC
1/LS
SNP/NN
in/IN
RHOQ/NNP
)/)
,/,
23/CD
SNPs/NNS
in/IN
introns/NNS
(/(
8/CD
SNPs/NNS
in/IN
CBL/NN
,/,
12/CD
SNPs/NNS
in/IN
SORBS1/NN
,/,
and/CC
3/LS
SNPs/NNS
in/IN
RHOQ/NNP
)/)
,/,
and/CC
7/CD
SNPs/NNS
in/IN
the/DT
3/LS
’/NNP
UTR/NN
(/(
3/LS
SNPs/NNS
in/IN
CRK/NN
and/CC
4/CD
SNPs/NNS
in/IN
SORBS1/NN
)/)
(/(
see/RBR
Supplementary/JJ
Table/JJ
3/LS
)/)
./.
====================
The/DT
locations/NNS
of/IN
these/DT
polymorphisms/NNS
in/IN
relation/NN
to/TO
the/DT
genomic/JJ
structures/NNS
of/IN
each/DT
participant/NN
in/IN
the/DT
CAP/TC10/NN
pathway/NN
are/VBP
described/VBN
in/IN
Supplementary/JJ
Fig/NN
./.
====================
1/CD
./.
====================
Next/RB
,/,
we/PRP
selected/VBD
10/CD
SNPs/NNS
for/IN
largerscale/JJ
genotyping/VBG
based/VBN
on/IN
LDs/NNS
,/,
position/NN
,/,
and/CC
frequencies/NNS
(/(
＞0.05/NN
)/)
./.
====================
The/DT
SNP/NN
positions/NNS
(/(
marked/JJ
with/IN
asterisks/NNS
in/IN
Supplementary/JJ
Fig/NN
./.
====================
1/LS
)/)
from/IN
the/DT
translation/NN
start/RB
site/NN
are/VBP
19147C＞T/JJ
(/(
rs3806202/NN
)/)
in/IN
the/DT
promoter/NN
region/NN
of/IN
SORBS1/NN
;/:
18485G＞T/RB
(/(
rs4077664/RB
)/)
in/IN
intron/NN
1/CD
of/IN
SORBS1/NN
;/:
+12922C＞A/CC
(/(
novel/JJ
)/)
in/IN
SORBS1/NN
exon/NN
13/CD
of/IN
the/DT
3/LS
’/NNP
untranslated/JJ
region/NN
(/(
3/LS
’/NNP
UTR/NN
)/)
;/:
+69002C＞T/RB
(/(
rs3794073/RB
)/)
in/IN
intron/NN
5/CD
of/IN
CBL/NN
;/:
+71446T＞G/RB
(/(
rs2510152/RB
)/)
in/IN
intron/NN
7/CD
of/IN
CBL/NN
;/:
+79066C＞T/RB
(/(
rs227988/RB
)/)
in/IN
exon/NN
11/CD
of/IN
CBL/NN
;/:
1617C/RB
>/RBR
A/DT
(/(
rs1376405/RB
)/)
,/,
1601G＞A/RB
(/(
rs1868844/RB
)/)
,/,
and/CC
1510T＞C/NN
(/(
rs3754554/RB
)/)
in/IN
the/DT
promoter/NN
region/NN
of/IN
RHOQ/NNP
;/:
and/CC
+751G＞A/CC
(/(
novel/JJ
)/)
in/IN
exon/NN
2/CD
./.
====================
No/DT
deviation/NN
from/IN
HardyWeinberg/JJ
equilibrium/NN
was/VBD
observed/VBN
in/IN
the/DT
genotype/NN
frequencies/NNS
of/IN
the/DT
10/CD
SNPs/NNS
in/IN
the/DT
1138/CD
nondiabetic/JJ
controls/NNS
./.
====================
Associations/NNS
of/IN
the/DT
10/CD
SNPs/NNS
with/IN
the/DT
risk/NN
of/IN
T2DM/NN
were/VBD
analyzed/VBN
using/VBG
logistic/JJ
regression/NN
,/,
with/IN
adjustments/NNS
for/IN
age/NN
,/,
sex/NN
,/,
and/CC
BMI/NN
as/IN
covariates/VBZ
./.
====================
The/DT
results/NNS
of/IN
the/DT
logistic/JJ
regression/NN
analysis/NN
are/VBP
described/VBN
in/IN
Table/JJ
2./FW
rs1376405/NN
,/,
located/JJ
in/IN
the/DT
promoter/NN
region/NN
of/IN
the/DT
RHOQ/NN
gene/NN
,/,
had/VBD
a/DT
risk/NN
for/IN
diabetes/NNS
in/IN
the/DT
recessive/JJ
mode/NN
,/,
with/IN
an/DT
odds/NNS
ratio/NN
of/IN
8.714/CD
(/(
C./FW
I/NN
./.
====================
1.714∼44.29/CD
)/)
and/CC
a/DT
pvalue=0.009/CD
in/IN
the/DT
comparison/NN
between/IN
nondiabetic/JJ
controls/NNS
and/CC
cases/NNS
./.
====================
Overexpression/NN
of/IN
the/DT
RHOQ/NN
gene/NN
has/VBZ
been/VBN
shown/VBN
to/TO
inhibit/VB
insulinstimulated/JJ
GLUT4/NN
translocation/NN
in/IN
adipocytes/NNS
(/(
Hou/NNP
and/CC
Pessin/NN
,/,
2007/CD
)/)
./.
====================
One/CD
hypothesis/NN
is/VBZ
that/DT
the/DT
genetic/JJ
variation/NN
,/,
rs1376405/NN
in/IN
the/DT
promoter/NN
region/NN
of/IN
RHOQ/NN
,/,
affects/VBZ
the/DT
expression/NN
level/NN
of/IN
TC10/NN
protein/NN
,/,
which/WDT
in/IN
turn/NN
influences/VBZ
Glut4/NN
translocation/NN
to/TO
the/DT
plas/NNS
ma/NN
membrane/NN
upon/IN
the/DT
insulin/NN
stimulus/NN
./.
====================
As/IN
a/DT
result/NN
,/,
the/DT
genetic/JJ
variation/NN
of/IN
the/DT
RHOQ/NN
gene/NN
could/MD
lead/VB
to/TO
the/DT
increased/VBN
susceptibility/NN
to/TO
the/DT
development/NN
of/IN
type/NN
2/CD
diabetes/NNS
mellitus/NN
in/IN
the/DT
Korean/JJ
population/NN
./.
====================
With/IN
further/RBR
functional/JJ
studies/NNS
in/IN
row/JJ
,/,
the/DT
rs1376405/NN
SNP/NN
in/IN
the/DT
RHOQ/NN
locus/NN
could/MD
be/VB
exploited/VBN
for/IN
the/DT
prediction/NN
of/IN
T2DM/NN
in/IN
the/DT
Korean/JJ
population/NN
./.
====================
